Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.

Trial Profile

Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2016 Results of a biomarker and efficacy analysis presented at the 41st European Society for Medical Oncology Congress.
    • 20 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top